CD6 Ligand Blocking to Balance Cancer Killing and Autoimmunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current checkpoint inhibitor therapies for breast cancer are limited by varying efficacy and severe autoimmune adverse events, and many breast cancer types are resistant to this form of immunotherapy.
Innovation Solution
Blocking the binding of CD6 on lymphocytes to CD318 and/or CD166 on cancer cells using agents such as monoclonal antibodies, such as UMCD6, to enhance cancer cell killing and prevent autoimmunity, potentially combined with other cancer therapies like chemotherapy or immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitor therapy is used to treat breast cancer, then immune response against cancer is enhanced, but severe autoimmune adverse events occur and efficacy varies
Solution Approach 1:
The patent segments the immune checkpoint pathway by targeting specific ligands (CD318, CD166) that bind to CD6 on lymphocytes, rather than using broad checkpoint inhibitors. This selective approach enhances cancer cell killing while minimizing off-target autoimmune effects by dividing the therapeutic action into specific molecular interactions.
Solution Approach 2:
The patent introduces blocking agents (antibodies or other molecules) as intermediaries that prevent the harmful interaction between CD6 on lymphocytes and CD318/CD166 on cancer cells. This intermediary blocks the pathological binding while allowing controlled immune response, resolving the contradiction between effective cancer killing and autoimmune side effects.
2Productivity
If checkpoint inhibitor therapy is used to treat breast cancer, then some cancer cells are killed, but many cancer types show resistance
Solution Approach 1:
The patent targets multiple ligands (CD318 and/or CD166) that can be expressed on different cancer types including breast cancer. By designing blocking agents that can interfere with either or both ligands binding to CD6, the therapy achieves multi-functionality across different cancer types, overcoming resistance issues while maintaining killing efficiency.
Data Source
AI summary
Provided herein are compositions and methods for cancer immunotherapy. In particular, provided herein are compositions and methods for blocking CD6 binding to ligands on cancer cells.